Faculty Profile

Arlene Chapman
Section of Nephrology
Professor of Medicine
Referring Physician Access Line: 1-877-DOM-2730
Chief, Section of Nephrology

Academic Interests

Dr. Chapman's research focuses on clinical manifestations of autosomal dominant polycystic kidney disease (ADPKD). Dr. Chapman has been heavily involved in the development of novel imaging biomarkers for this disease using magnetic resonance imaging and calculating total kidney volume (TKV). Clinical trials testing appropriate levels of blood pressure control, inhibition of the vasopressin V2 receptor, epidermal growth factor receptor inhibition and alterations in fluid intake and dietary amino acids and their impact on disease progression are currently active.. Dr. Chapman also studies personalized or precision medicine and the role that genetic background plays in predicting antihypertensive responses to blood pressure medications used to treat hypertension as well as disease progression in ADPKD. Dr. Chapman's early investigations centered on demonstrating that the renal and systemic changes that occur during pregnancy happen early, by the sixth week of pregnancy. She has received continuous funding for her work from the National Institutes of Health (NIH) over the past 20 years.

Clinical Interests

Hereditary renal diseases, specifically autosomal dominant polycystic kidney disease, as well as other rare conditions including autosomal recessive kidney diseases, the CAKUT disorders, ciliopathies, tuberous sclerosis complex and von Hippel Lindau disease.


  • Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Perrone RD, Koch G, Ouyang J, McQuade RD, Blais JD, Czerwiec FS, Sergeyeva O; REPRISE Trial Investigators. Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease. N Engl J Med. 2017 Nov 16;377(20):1930-1942. doi: 10.1056/NEJMoa1710030. Epub 2017 Nov 4. PMID: 29105594.
  • Singh S, McDonough CW, Gong Y, Alghamdi WA, Arwood MJ, Bargal SA, Dumeny L, Li WY, Mehanna M, Stockard B, Yang G, de Oliveira FA, Fredette NC, Shahin MH, Bailey KR, Beitelshees AL, Boerwinkle E, Chapman AB, et al. Genome Wide Association Study Identifies the HMGCS2 Locus to be Associated With Chlorthalidone Induced Glucose Increase in Hypertensive Patients. J Am Heart Assoc. 2018 Mar 20;7(6):e007339. doi: 10.1161/JAHA.117.007339. PMID: 29523524.
  • Chapman A, Devusyt O, Gansevoort R, Perrone R, Torres V, Czerwiec F, et al. Potential Impact of Tolvaptan on Blood Pressure in the Tempo 3:4 Patient Population. Nephrol Dial Transplant. 2018 May;33. doi: 10.1093/ndt/gfy104.FP047.
  • Dad T, Abebe KZ, Bae KT, Comer D, Torres VE, Czarnecki PG, Schrier RW, Steinman TI, Moore CG, Chapman AB, et al. Longitudinal Assessment of Left Ventricular Mass in Autosomal Dominant Polycystic Kidney Disease. Kidney Int Rep. 2018 May;3(3):619–24. doi: 10.1016/j.ekir.2017.12.011. eCollection 2018 May. PMID: 29854969.
  • Sa ACC, Webb A, Gong Y, McDonough CW, Shahin MH, Datta S, Langaee TY, Turner ST, Beitelshees AL, Chapman AB, et al. Blood pressure signature genes and blood pressure response to thiazide diuretics: results from the PEAR and PEAR-2 studies. BMC Med Genomics. 2018 Jun 20;11:55. doi: 10.1186/s12920-018-0370-x. PMID: 29925376.
For a complete list of publications click here:


  • MD, 1983, McMaster University,
  • Internship, 1984, Georgetown University Hospital, Internal Medicine
  • Residency, 1986, Georgetown University Hospital, Internal Medicine
  • Fellowship, 1987, Georgetown University Hospital, Nephrology
  • Fellowship, 1988, Georgetown University Hospital, Nephrology
  • Fellowship, 1989, University of Colorado Health Sciences Center, Nephrology